新的研究表明,Gantenerumab药物可能会将阿尔茨海默氏症的症状推迟50%,因为市场到2031年将增长到9.3B。 New study shows drug Gantenerumab could delay Alzheimer's symptoms by 50%, as market grows to $9.3B by 2031.

阿尔茨海默氏病相关痴呆症的全球市场正在增长,预计到2031年将达到93亿美元,其驱动力是人口老龄化和药物开发的进步。 The global market for Alzheimer's-related dementia is growing, expected to reach $9.3 billion by 2031, driven by an aging population and advancements in drug development. 一项新的研究表明,Gantenerumab药物可能会将遗传病易发人的阿尔茨海默氏病征延迟50%。 A new study shows that the drug Gantenerumab could delay Alzheimer's symptoms by 50% in genetically predisposed individuals. 与此同时，“与阿尔茨海默病相关的痴呆症管道洞察 2025”报告重点介绍了 80 多家公司正在开发 100 多种潜在疗法。 Meanwhile, the "Dementia Associated With Alzheimer's Disease Pipeline Insight 2025" report highlights over 80 companies working on more than 100 potential therapies.